Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
11 June 2019 - Posted by: Sophie ten Bosch
At the latest meeting of EU agriculture ministers, and following a report by the Danish Council of Ethics, 14 EU member states, led by the Netherlands and Estonia, called for the European Commission to re-evaluate the EU’s stance on genetically modified organisms (GMOs), in particular those created by new plant breeding techniques. In a ruling › Read More
10 June 2019 - Posted by: Jacqueline Bore
The EU’s General Court, whose jurisdiction includes the judicial review of decisions made by the EU institutions such as European Medicines Agency, has recently considered an interesting application in relation to a medicinal product that had been granted orphan designation on the little used basis that its significant benefit lay in its potential authorisation in › Read More
04 June 2019 - Posted by: Eveline Van Keymeulen
On 6 May 2019, the French National Agency of Medicine and Health Products Safety (ANSM), facing the challenges of stock shortages and the risks of introducing falsified medicines into circulation, published an announcement on action against “short-liner” wholesale distributors. Wholesale distributors, holding authorisations granted by the ANSM, carry out the purchase, sale, storage and distribution › Read More
26 May 2019 - Posted by: Kaat Van Delm
On 7 April 2019, a law altering the notification procedure for implants and certain invasive medical devices for long-term use was adopted. Previously, the Belgian Sickness and Invalidity Institute (INAMI) needed to be notified if implants and certain invasive medical devices were used long-term, while distributors of medical devices were required to register with the › Read More
20 May 2019 - Posted by: Laurie-Anne Ancenys
The French Office parlementaire d’évaluation des choix scientifiques (the Office) has published a report on artificial intelligence and health data following the public hearing organised in February 2019, in the form of two round tables on artificial intelligence and health data. The hearing, attended by AI researchers, entrepreneurs, public and private stakeholders of the health › Read More